XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and License Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2016
target
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
obligation
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
License related revenue   $ 0 $ 515,000 $ 30,000,000 $ 2,141,000  
GSK Agreement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Contract with customer, expiration period       10 years    
Number of performance obligations | obligation       3    
Transaction price   90,264,000   $ 90,264,000    
GSK Agreement | License            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
License related revenue   0 515,000 30,000,000 2,141,000  
GSK Agreement | License | Transferred at Point in Time            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront payment   85,000,000   85,000,000    
License related revenue           $ 85,000,000
GSK Agreement | License | Transferred over Time            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Additional payments to be received   4,314,000   4,314,000    
GSK Agreement | Transition Services            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
License related revenue   0 299,000   661,000  
GSK Agreement | Transition Services | Transferred over Time            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Additional payments to be received   950,000   950,000    
GSK Agreement | Supply Services            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
License related revenue     216,000 0 1,480,000  
GSK Agreement | Clinical Milestone Payment            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestones payment       60,000,000    
GSK Agreement | Regulatory Milestone Payment            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestones payment       155,000,000    
GSK Agreement | Sales Milestone Payment            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestones payment       485,000,000    
Novartis Collaboration            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Number of option targets | target 4          
Number of option targets purchased | target 3          
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc.            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue   $ 0 $ 0 0 $ 0  
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc. | Development Milestone            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestones payment       325,000,000    
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc. | Sales Milestone            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestones payment       $ 200,000,000